Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Future OncologyOpen Access

Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

SRShinya RaiBC Cancer AgencyYTYoshinori TanizawaEli Lilly (Japan)TTTomoko TerasawaEli Lilly (United States)

Discussion

Loading...

Member takes

Implication

Cross-sectional survey detailing disease management and treatment responses in MCL patients, highlighting the role of BTKi.

Key Points

  • Patients with mantle cell lymphoma showed a complete response rate of 47.8% to first-line treatment, with mixed responses to relapsed therapies.
  • The most prevalent initial symptom among patients was painless swelling, reported in 72% of cases, indicating a need for awareness.
  • Retrospective data collection included 67 patients, primarily male, with a median age of 69.4 years, lending insights into the disease landscape.
  • Physicians indicated the primary treatment goal was to minimize impacts on daily life, emphasizing quality of life alongside therapeutic response.

Cite This Study

Rai et al. (2025) studied this question.

synapsesocial.com/papers/68c23d3ab210217d6478d5b0https://doi.org/10.1080/14796694.2025.2555165
View Full Paper
Ask AI
Bookmark
Share